Table 2. Diagnostic accuracy of predictors and prediction models in predicting prostate cancer or significant prostate cancer.
| Predictors | Predicting PCa | Predicting Significant PCa | |||
|---|---|---|---|---|---|
| AUC | 95% CI | AUC | 95% CI | ||
| All Pts (n = 247) | tPSA | 0.679 | 0.609–0.749 | 0.722 | 0.652–0.792 |
| PZ-ratio | 0.672 | 0.603–0.741 | 0.659 | 0.588–0.730 | |
| MRI | 0.758 | 0.707–0.808 | 0.760 | 0.711–0.809 | |
| PSAD | 0.757 | 0.694–0.820 | 0.781 | 0.717–0.844 | |
| %fPSA | 0.657 | 0.588–0.726 | 0.653 | 0.583–0.724 | |
| Model | 0.812 | 0.758–0.866 | 0.843 | 0.792–0.893 | |
| Model+PZ-ratio | 0.839 | 0.787–0.891 | 0.869 | 0.822–0.917 | |
| Model+MRI | 0.854 | 0.807–0.900 | 0.874 | 0.830–0.919 | |
| Model+MRI+PZ-ratio | 0.871 | 0.825–0.917 | 0.890 | 0.845–0.934 | |
| Pts PSA 4–10 ng/ml (n = 108) | tPSA | 0.565 | 0.441–0.688 | 0.522 | 0.389–0.655 |
| PZ-ratio | 0.676 | 0.557–0.795 | 0.642 | 0.498–0.786 | |
| MRI | 0.747 | 0.663–0.832 | 0.777 | 0.704–0.850 | |
| PSAD | 0.729 | 0.620–0.839 | 0.692 | 0.555–0.830 | |
| %fPSA | 0.664 | 0.550–0.779 | 0.632 | 0.498–0.766 | |
| Model | 0.803 | 0.693–0.913 | 0.846 | 0.728–0.964 | |
| Model+PZ-ratio | 0.851 | 0.766–0.936 | 0.862 | 0.747–0.976 | |
| Model+MRI | 0.822 | 0.715–0.929 | 0.888 | 0.792–0.984 | |
| Model+MRI+PZ-ratio | 0.863 | 0.776–0.951 | 0.899 | 0.795–1.000 | |
PCa: prostate cancer; PSA: prostate-specific antigen; PZ-ratio: peripheral zone ratio; MRI: magnetic resonance imaging; OR: odds ratio; CI: confidence interval; AUC: area under the curve.